GORTEC (Head and Neck Oncology and Radiotherapy Group) Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2020
NCT04459715
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

GORTEC (Head and Neck Oncology and Radiotherapy Group)

Active Ingredients

Drugs in Phase 3 Trials (2)

cisplatin (platinol) (1 trial)

debio 1143 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2